| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| TEVA - Teva Pharma Industries Ltd ADR | BUY | 598 @ USD 24.46 | USD 14,627 | The ETF bought 598 new shares of TEVA (Teva Pharma Industries Ltd ADR). The shares were bought for an average price of 24.46 compared to the previous average buy price of 18.1566. This is 34.7% higher than average price of previous purchases of TEVA. |
| 2413.T - M3, Inc. | HOLD | 0 @ JPY 13.675 | JPY 0 | The current share valuation price of 2413.T based on adjusted close was JPY 13.675. The average price that 2413.T shares were previous bought at was JPY 14.2637. The current market price is -4.1% lower than average price they were purchased at. The value of the holding in 2413.T has fallen by JPY 13,655 compared to the previous valuation of M3, Inc. |
| 4151.T - Kyowa Kirin Co., Ltd. | HOLD | 0 @ JPY 15.6705 | JPY 0 | The current share valuation price of 4151.T based on adjusted close was JPY 15.6705. The average price that 4151.T shares were previous bought at was JPY 15.513. The current market price is 1.0% higher than average price they were purchased at. The value of the holding in 4151.T has increased by JPY 22,911 compared to the previous valuation of Kyowa Kirin Co., Ltd. however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| 4502.T - Takeda Pharmaceutical Company Limited | HOLD | 0 @ JPY 27.3761 | JPY 0 | The current share valuation price of 4502.T based on adjusted close was JPY 27.3761. The average price that 4502.T shares were previous bought at was JPY 28.7966. The current market price is -4.9% lower than average price they were purchased at. The value of the holding in 4502.T has increased by JPY 13,338 compared to the previous valuation of Takeda Pharmaceutical Company Limited however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| 4503.T - Astellas Pharma Inc. | HOLD | 0 @ JPY 11.3789 | JPY 0 | The current share valuation price of 4503.T based on adjusted close was JPY 11.3789. The average price that 4503.T shares were previous bought at was JPY 10.6945. The current market price is 6.4% higher than average price they were purchased at. The value of the holding in 4503.T has increased by JPY 267,940 compared to the previous valuation of Astellas Pharma Inc. however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| 4507.T - Shionogi & Co., Ltd. | HOLD | 0 @ JPY 17.1403 | JPY 0 | The current share valuation price of 4507.T based on adjusted close was JPY 17.1403. The average price that 4507.T shares were previous bought at was JPY 16.8344. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in 4507.T has increased by JPY 4,909 compared to the previous valuation of Shionogi & Co., Ltd. however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | HOLD | 0 @ JPY 45.4047 | JPY 0 | The current share valuation price of 4519.T based on adjusted close was JPY 45.4047. The average price that 4519.T shares were previous bought at was JPY 45.8615. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in 4519.T has increased by JPY 449 compared to the previous valuation of Chugai Pharmaceutical Co., Ltd. however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 28.5061 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 28.5061. The average price that 4523.T shares were previous bought at was JPY 30.3993. The current market price is -6.2% lower than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 36,232 compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| 4543.T - Terumo Corporation | HOLD | 0 @ JPY 16.2682 | JPY 0 | The current share valuation price of 4543.T based on adjusted close was JPY 16.2682. The average price that 4543.T shares were previous bought at was JPY 16.7591. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in 4543.T has increased by JPY 2,394 compared to the previous valuation of Terumo Corporation however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| 4568.T - Daiichi Sankyo Company, Limited | HOLD | 0 @ JPY 22.281 | JPY 0 | The current share valuation price of 4568.T based on adjusted close was JPY 22.281. The average price that 4568.T shares were previous bought at was JPY 27.6546. The current market price is -19.4% lower than average price they were purchased at. The value of the holding in 4568.T has increased by JPY 115,971 compared to the previous valuation of Daiichi Sankyo Company, Limited however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| 4578.T - Otsuka Holdings Co., Ltd. | HOLD | 0 @ JPY 55.5948 | JPY 0 | The current share valuation price of 4578.T based on adjusted close was JPY 55.5948. The average price that 4578.T shares were previous bought at was JPY 55.5796. The current market price is 0.0% higher than average price they were purchased at. The value of the holding in 4578.T has increased by JPY 8,166 compared to the previous valuation of Otsuka Holdings Co., Ltd. however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 10.5167 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 10.5167. The average price that 6869.T shares were previous bought at was JPY 12.5573. The current market price is -16.3% lower than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 107,557 compared to the previous valuation of Sysmex Corporation |
| 7733.T - Olympus Corporation | HOLD | 0 @ JPY 12.0158 | JPY 0 | The current share valuation price of 7733.T based on adjusted close was JPY 12.0158. The average price that 7733.T shares were previous bought at was JPY 12.6166. The current market price is -4.8% lower than average price they were purchased at. The value of the holding in 7733.T has fallen by JPY 161 compared to the previous valuation of Olympus Corporation |
| 7741.T - HOYA Corporation | HOLD | 0 @ JPY 167.385 | JPY 0 | The current share valuation price of 7741.T based on adjusted close was JPY 167.385. The average price that 7741.T shares were previous bought at was JPY 135.742. The current market price is 23.3% higher than average price they were purchased at. The value of the holding in 7741.T has increased by JPY 47,244 compared to the previous valuation of HOYA Corporation however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 147.49 | USD 0 | The current share valuation price of A based on adjusted close was USD 147.49. The average price that A shares were previous bought at was USD 135.277. The current market price is 9.0% higher than average price they were purchased at. The value of the holding in A has increased by USD 63,810 compared to the previous valuation of Agilent Technologies Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 219.04 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 219.04. The average price that ABBV shares were previous bought at was USD 204.201. The current market price is 7.3% higher than average price they were purchased at. The value of the holding in ABBV has increased by USD 285,335 compared to the previous valuation of AbbVie Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 124.95 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 124.95. The average price that ABT shares were previous bought at was USD 132.169. The current market price is -5.5% lower than average price they were purchased at. The value of the holding in ABT has increased by USD 33,436 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| ALC.SW - | HOLD | 0 @ CHF 73.5473 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 73.5473. The average price that ALC.SW shares were previous bought at was CHF 77.9566. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in ALC.SW has fallen by CHF 30,982 compared to the previous valuation of |
| ALGN - Align Technology Inc | HOLD | 0 @ USD 133.73 | USD 0 | The current share valuation price of ALGN based on adjusted close was USD 133.73. The average price that ALGN shares were previous bought at was USD 135.875. The current market price is -1.6% lower than average price they were purchased at. The value of the holding in ALGN has fallen by USD 6,393 compared to the previous valuation of Align Technology Inc |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 440.49 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 440.49. The average price that ALNY shares were previous bought at was USD 414.737. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in ALNY has increased by USD 45,222 compared to the previous valuation of Alnylam Pharmaceuticals Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 315.59 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 315.59. The average price that AMGN shares were previous bought at was USD 289.67. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in AMGN has fallen by USD 117,233 compared to the previous valuation of Amgen Inc |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 850.923 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 850.923. The average price that ARGX.BR shares were previous bought at was EUR 714.954. The current market price is 19.0% higher than average price they were purchased at. The value of the holding in ARGX.BR has increased by EUR 40,838 compared to the previous valuation of Argenx SE however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 168.157 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 168.157. The average price that AZN.L shares were previous bought at was GBP 133.937. The current market price is 25.5% higher than average price they were purchased at. The value of the holding in AZN.L has increased by GBP 1,032,838 compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| BAX - Baxter International Inc | HOLD | 0 @ USD 17.98 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 17.98. The average price that BAX shares were previous bought at was USD 22.3875. The current market price is -19.7% lower than average price they were purchased at. The value of the holding in BAX has increased by USD 312 compared to the previous valuation of Baxter International Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 30.5912 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 30.5912. The average price that BAYN.DE shares were previous bought at was EUR 31.1449. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in BAYN.DE has increased by EUR 4,923 compared to the previous valuation of Bayer AG however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| BDX - Becton Dickinson and Company | HOLD | 0 @ USD 177.39 | USD 0 | The current share valuation price of BDX based on adjusted close was USD 177.39. The average price that BDX shares were previous bought at was USD 182.841. The current market price is -3.0% lower than average price they were purchased at. The value of the holding in BDX has increased by USD 5,971 compared to the previous valuation of Becton Dickinson and Company however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 156.74 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 156.74. The average price that BIIB shares were previous bought at was USD 144.991. The current market price is 8.1% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 9,645 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 121.626 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 121.626. The average price that BIM.PA shares were previous bought at was EUR 129.948. The current market price is -6.4% lower than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 4,773 compared to the previous valuation of BioMerieux |
| BMRN - Biomarin Pharmaceutical Inc | HOLD | 0 @ USD 51.8399 | USD 0 | The current share valuation price of BMRN based on adjusted close was USD 51.8399. The average price that BMRN shares were previous bought at was USD 56.2324. The current market price is -7.8% lower than average price they were purchased at. The value of the holding in BMRN has fallen by USD 4,043 compared to the previous valuation of Biomarin Pharmaceutical Inc |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 46.63 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 46.63. The average price that BMY shares were previous bought at was USD 47.1527. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in BMY has increased by USD 13,748 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 99.05 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 99.05. The average price that BSX shares were previous bought at was USD 101.398. The current market price is -2.3% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 4,841 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 99.05 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 99.05. The average price that BSX shares were previous bought at was USD 101.398. The current market price is -2.3% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 4,841 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| CAH - Cardinal Health Inc | HOLD | 0 @ USD 197.99 | USD 0 | The current share valuation price of CAH based on adjusted close was USD 197.99. The average price that CAH shares were previous bought at was USD 165.397. The current market price is 19.7% higher than average price they were purchased at. The value of the holding in CAH has increased by USD 88,766 compared to the previous valuation of Cardinal Health Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| CI - Cigna Corp | HOLD | 0 @ USD 256.38 | USD 0 | The current share valuation price of CI based on adjusted close was USD 256.38. The average price that CI shares were previous bought at was USD 292.391. The current market price is -12.3% lower than average price they were purchased at. The value of the holding in CI has fallen by USD 137,612 compared to the previous valuation of Cigna Corp |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 37.1 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 37.1. The average price that CNC shares were previous bought at was USD 39.361. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in CNC has increased by USD 30,334 compared to the previous valuation of Concurrent Technologies Plc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| COH.AX - | HOLD | 0 @ AUD 184.467 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 184.467. The average price that COH.AX shares were previous bought at was AUD 185.498. The current market price is -0.6% lower than average price they were purchased at. The value of the holding in COH.AX has fallen by AUD 16,759 compared to the previous valuation of |
| COLO-B.CO - | HOLD | 0 @ DKK 94.8105 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 94.8105. The average price that COLO-B.CO shares were previous bought at was DKK 92.4839. The current market price is 2.5% higher than average price they were purchased at. The value of the holding in COLO-B.CO has increased by DKK 13,344 compared to the previous valuation of however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 69 | USD 0 | The current share valuation price of COO based on adjusted close was USD 69. The average price that COO shares were previous bought at was USD 70.1887. The current market price is -1.7% lower than average price they were purchased at. The value of the holding in COO has increased by USD 474 compared to the previous valuation of The Cooper Companies, Inc. Common Stock however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| COR - Cencora Inc. | HOLD | 0 @ USD 360.24 | USD 0 | The current share valuation price of COR based on adjusted close was USD 360.24. The average price that COR shares were previous bought at was USD 318.212. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in COR has increased by USD 303,982 compared to the previous valuation of Cencora Inc. however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| CSL.AX - | HOLD | 0 @ AUD 116.139 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 116.139. The average price that CSL.AX shares were previous bought at was AUD 132.252. The current market price is -12.2% lower than average price they were purchased at. The value of the holding in CSL.AX has increased by AUD 15,068 compared to the previous valuation of however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| CVS - CVS Health Corp | HOLD | 0 @ USD 78.66 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 78.66. The average price that CVS shares were previous bought at was USD 68.7988. The current market price is 14.3% higher than average price they were purchased at. The value of the holding in CVS has increased by USD 6,507 compared to the previous valuation of CVS Health Corp however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| DEMANT.CO - | HOLD | 0 @ DKK 34.499 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 34.499. The average price that DEMANT.CO shares were previous bought at was DKK 35.7818. The current market price is -3.6% lower than average price they were purchased at. The value of the holding in DEMANT.CO has fallen by DKK 8,940 compared to the previous valuation of |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 176.51 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 176.51. The average price that DGX shares were previous bought at was USD 180.581. The current market price is -2.3% lower than average price they were purchased at. The value of the holding in DGX has fallen by USD 3,817 compared to the previous valuation of Quest Diagnostics Incorporated |
| DHR - Danaher Corporation | HOLD | 0 @ USD 210.67 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 210.67. The average price that DHR shares were previous bought at was USD 198.694. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 47,086 compared to the previous valuation of Danaher Corporation |
| DHR - Danaher Corporation | HOLD | 0 @ USD 210.67 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 210.67. The average price that DHR shares were previous bought at was USD 198.694. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 47,086 compared to the previous valuation of Danaher Corporation |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 219.712 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 219.712. The average price that DIM.PA shares were previous bought at was EUR 220.877. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in DIM.PA has fallen by EUR 3,752 compared to the previous valuation of Sartorius Stedim Biotech |
| DVA - DaVita HealthCare Partners Inc | HOLD | 0 @ USD 121.53 | USD 0 | The current share valuation price of DVA based on adjusted close was USD 121.53. The average price that DVA shares were previous bought at was USD 128.185. The current market price is -5.2% lower than average price they were purchased at. The value of the holding in DVA has increased by USD 723 compared to the previous valuation of DaVita HealthCare Partners Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 58.02 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 58.02. The average price that DXCM shares were previous bought at was USD 71.3092. The current market price is -18.6% lower than average price they were purchased at. The value of the holding in DXCM has fallen by USD 12,901 compared to the previous valuation of DexCom Inc |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 360.84 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 360.84. The average price that EL.PA shares were previous bought at was EUR 319.13. The current market price is 13.1% higher than average price they were purchased at. The value of the holding in EL.PA has fallen by EUR 19,513 compared to the previous valuation of EssilorLuxottica SA |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 314.44 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 314.44. The average price that ELV shares were previous bought at was USD 381.913. The current market price is -17.7% lower than average price they were purchased at. The value of the holding in ELV has fallen by USD 148,673 compared to the previous valuation of Elevance Health Inc |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 314.44 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 314.44. The average price that ELV shares were previous bought at was USD 381.913. The current market price is -17.7% lower than average price they were purchased at. The value of the holding in ELV has fallen by USD 148,673 compared to the previous valuation of Elevance Health Inc |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 67.6446 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 67.6446. The average price that ERF.PA shares were previous bought at was EUR 54.3413. The current market price is 24.5% higher than average price they were purchased at. The value of the holding in ERF.PA has fallen by EUR 608 compared to the previous valuation of Eurofins Scientific SE |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 82.44 | USD 0 | The current share valuation price of EW based on adjusted close was USD 82.44. The average price that EW shares were previous bought at was USD 78.2923. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in EW has fallen by USD 48,944 compared to the previous valuation of Edwards Lifesciences Corp |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 48.5121 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 48.5121. The average price that FME.DE shares were previous bought at was EUR 51.4499. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in FME.DE has increased by EUR 3,044 compared to the previous valuation of Fresenius Medical Care AG however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| FPH.NZ - | HOLD | 0 @ NZD 21.4785 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 21.4785. The average price that FPH.NZ shares were previous bought at was NZD 21.107. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in FPH.NZ has increased by NZD 1,515 compared to the previous valuation of however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 55.6781 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 55.6781. The average price that FRE.DE shares were previous bought at was EUR 52.4661. The current market price is 6.1% higher than average price they were purchased at. The value of the holding in FRE.DE has increased by EUR 4,684 compared to the previous valuation of Fresenius SE & Co KGaA however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| GALD.SW - | HOLD | 0 @ CHF 183.372 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 183.372. The average price that GALD.SW shares were previous bought at was CHF 173.378. The current market price is 5.8% higher than average price they were purchased at. The value of the holding in GALD.SW has increased by CHF 7,674 compared to the previous valuation of however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 74.17 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 74.17. The average price that GEHC shares were previous bought at was USD 78.2367. The current market price is -5.2% lower than average price they were purchased at. The value of the holding in GEHC has fallen by USD 13,409 compared to the previous valuation of GE HealthCare Technologies Inc. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 123.4 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 123.4. The average price that GILD shares were previous bought at was USD 115.808. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 124,414 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 288.651 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 288.651. The average price that GMAB.CO shares were previous bought at was DKK 284.143. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 123,227 compared to the previous valuation of however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 12.0242 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 12.0242. The average price that GRF.MC shares were previous bought at was EUR 13.372. The current market price is -10.1% lower than average price they were purchased at. The value of the holding in GRF.MC has fallen by EUR 6,300 compared to the previous valuation of Grifols SA |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 23.3028 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 23.3028. The average price that GSK.L shares were previous bought at was GBP 21.6478. The current market price is 7.6% higher than average price they were purchased at. The value of the holding in GSK.L has fallen by GBP 1,310 compared to the previous valuation of GlaxoSmithKline PLC |
| HCA - HCA Holdings Inc | HOLD | 0 @ USD 471.36 | USD 0 | The current share valuation price of HCA based on adjusted close was USD 471.36. The average price that HCA shares were previous bought at was USD 436.774. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in HCA has fallen by USD 7,207 compared to the previous valuation of HCA Holdings Inc |
| HIK.L - | HOLD | 0 @ GBP 19.942 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 19.942. The average price that HIK.L shares were previous bought at was GBP 24.113. The current market price is -17.3% lower than average price they were purchased at. The value of the holding in HIK.L has fallen by GBP 34,113 compared to the previous valuation of |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 4.69724 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 4.69724. The average price that HLN.L shares were previous bought at was GBP 4.94029. The current market price is -4.9% lower than average price they were purchased at. The value of the holding in HLN.L has increased by GBP 7,140 compared to the previous valuation of Haleon PLC however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.15 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.15. The average price that HOLX shares were previous bought at was USD 70.0245. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in HOLX has fallen by USD 7,123 compared to the previous valuation of Hologic Inc |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 251.11 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 251.11. The average price that HUM shares were previous bought at was USD 302.069. The current market price is -16.9% lower than average price they were purchased at. The value of the holding in HUM has fallen by USD 254,444 compared to the previous valuation of Hummingbird Resources PLC |
| HUM - Humana Inc | HOLD | 0 @ USD 251.11 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 251.11. The average price that HUM shares were previous bought at was USD 302.069. The current market price is -16.9% lower than average price they were purchased at. The value of the holding in HUM has fallen by USD 254,444 compared to the previous valuation of Humana Inc |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 713.74 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 713.74. The average price that IDXX shares were previous bought at was USD 606.673. The current market price is 17.6% higher than average price they were purchased at. The value of the holding in IDXX has fallen by USD 101,870 compared to the previous valuation of IDEXX Laboratories Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 121.11 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 121.11. The average price that ILMN shares were previous bought at was USD 100.693. The current market price is 20.3% higher than average price they were purchased at. The value of the holding in ILMN has fallen by USD 4,101 compared to the previous valuation of Illumina Inc |
| INCY - Incyte Corporation | HOLD | 0 @ USD 105.2 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 105.2. The average price that INCY shares were previous bought at was USD 89.2644. The current market price is 17.9% higher than average price they were purchased at. The value of the holding in INCY has fallen by USD 1,781 compared to the previous valuation of Incyte Corporation |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 142.051 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 142.051. The average price that IPN.PA shares were previous bought at was EUR 135.278. The current market price is 5.0% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 1,508 compared to the previous valuation of Ipsen SA however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 210.86 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 210.86. The average price that IQV shares were previous bought at was USD 200.321. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in IQV has increased by USD 37,254 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 547.78 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 547.78. The average price that ISRG shares were previous bought at was USD 530.349. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in ISRG has fallen by USD 15,225 compared to the previous valuation of Intuitive Surgical Inc |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 186.97 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 186.97. The average price that JNJ shares were previous bought at was USD 167.147. The current market price is 11.9% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 138,147 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 246.64 | USD 0 | The current share valuation price of LH based on adjusted close was USD 246.64. The average price that LH shares were previous bought at was USD 263.732. The current market price is -6.5% lower than average price they were purchased at. The value of the holding in LH has fallen by USD 6,755 compared to the previous valuation of Laboratory Corporation of America Holdings |
| LLY - Eli Lilly and Company | HOLD | 0 @ USD 937.44 | USD 0 | The current share valuation price of LLY based on adjusted close was USD 937.44. The average price that LLY shares were previous bought at was USD 825.812. The current market price is 13.5% higher than average price they were purchased at. The value of the holding in LLY has increased by USD 718,118 compared to the previous valuation of Eli Lilly and Company however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| LONN.SW - | HOLD | 0 @ CHF 658.654 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 658.654. The average price that LONN.SW shares were previous bought at was CHF 676.676. The current market price is -2.7% lower than average price they were purchased at. The value of the holding in LONN.SW has fallen by CHF 7,268 compared to the previous valuation of |
| MCK - McKesson Corporation | HOLD | 0 @ USD 858.61 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 858.61. The average price that MCK shares were previous bought at was USD 773.946. The current market price is 10.9% higher than average price they were purchased at. The value of the holding in MCK has increased by USD 295,352 compared to the previous valuation of McKesson Corporation however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 90.06 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 90.06. The average price that MDT shares were previous bought at was USD 91.6287. The current market price is -1.7% lower than average price they were purchased at. The value of the holding in MDT has fallen by USD 9,171 compared to the previous valuation of Medtronic PLC |
| MOH - MOH | HOLD | 0 @ USD 147.12 | USD 0 | The current share valuation price of MOH based on adjusted close was USD 147.12. The average price that MOH shares were previous bought at was USD 201.322. The current market price is -26.9% lower than average price they were purchased at. The value of the holding in MOH has fallen by USD 38,527 compared to the previous valuation of MOH |
| MOH - LVMH Moët Hennessy - Louis Vuitton Société Européenne | HOLD | 0 @ USD 147.12 | USD 0 | The current share valuation price of MOH based on adjusted close was USD 147.12. The average price that MOH shares were previous bought at was USD 201.322. The current market price is -26.9% lower than average price they were purchased at. The value of the holding in MOH has fallen by USD 38,527 compared to the previous valuation of LVMH Moët Hennessy - Louis Vuitton Société Européenne |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 85.78 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 85.78. The average price that MRK shares were previous bought at was USD 89.6219. The current market price is -4.3% lower than average price they were purchased at. The value of the holding in MRK has increased by USD 196,065 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 85.78 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 85.78. The average price that MRK shares were previous bought at was USD 89.6219. The current market price is -4.3% lower than average price they were purchased at. The value of the holding in MRK has increased by USD 196,065 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 127.281 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 127.281. The average price that MRK.DE shares were previous bought at was EUR 130.82. The current market price is -2.7% lower than average price they were purchased at. The value of the holding in MRK.DE has increased by EUR 1,112 compared to the previous valuation of Merck KGaA however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1439.62 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1439.62. The average price that MTD shares were previous bought at was USD 1324.02. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in MTD has fallen by USD 45 compared to the previous valuation of Mettler-Toledo International Inc |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1439.62 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1439.62. The average price that MTD shares were previous bought at was USD 1324.02. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in MTD has fallen by USD 45 compared to the previous valuation of AMUNDI EUR GOV 710 |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 154.8 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 154.8. The average price that NBIX shares were previous bought at was USD 140.876. The current market price is 9.9% higher than average price they were purchased at. The value of the holding in NBIX has increased by USD 2,295 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 126.279 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 126.279. The average price that NOVN.SW shares were previous bought at was CHF 122.389. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 263,430 compared to the previous valuation of however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 47.4439 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 47.4439. The average price that NOVO-B.CO shares were previous bought at was DKK 56.1956. The current market price is -15.6% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has increased by DKK 373,861 compared to the previous valuation of Novo Nordisk A/S however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 198.48 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 198.48. The average price that NTRA shares were previous bought at was USD 170.421. The current market price is 16.5% higher than average price they were purchased at. The value of the holding in NTRA has fallen by USD 4,351 compared to the previous valuation of Natera Inc |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 66.4098 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 66.4098. The average price that ORNBV.HE shares were previous bought at was EUR 67.2304. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in ORNBV.HE has fallen by EUR 1,004 compared to the previous valuation of Orion Oyj |
| PFE - Pfizer Inc | HOLD | 0 @ USD 24.85 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 24.85. The average price that PFE shares were previous bought at was USD 24.6374. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in PFE has increased by USD 50,576 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 28.2026 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 28.2026. The average price that PHIA.AS shares were previous bought at was EUR 26.5931. The current market price is 6.1% higher than average price they were purchased at. The value of the holding in PHIA.AS has increased by EUR 4,334 compared to the previous valuation of Koninklijke Philips NV however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 164.286 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 164.286. The average price that PME.AX shares were previous bought at was AUD 181.054. The current market price is -9.3% lower than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 1,699 compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 323.4 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 323.4. The average price that PODD shares were previous bought at was USD 313.923. The current market price is 3.0% higher than average price they were purchased at. The value of the holding in PODD has increased by USD 12,553 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 43.1058 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 43.1058. The average price that QIA.DE shares were previous bought at was EUR 45.509. The current market price is -5.3% lower than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 65,117 compared to the previous valuation of QIAGEN NV |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 57.8129 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 57.8129. The average price that REC.MI shares were previous bought at was EUR 58.4047. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in REC.MI has fallen by EUR 2,585 compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 646.87 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 646.87. The average price that REGN shares were previous bought at was USD 594.545. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in REGN has increased by USD 8,364 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| RMD - ResMed Inc | HOLD | 0 @ USD 249.65 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 249.65. The average price that RMD shares were previous bought at was USD 264.031. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in RMD has increased by USD 13,676 compared to the previous valuation of ResMed Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 343.452 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 343.452. The average price that RO.SW shares were previous bought at was CHF 341.923. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 26,970 compared to the previous valuation of however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 328.584 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 328.584. The average price that ROG.SW shares were previous bought at was CHF 325.693. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 44,525 compared to the previous valuation of however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 40.7799 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 40.7799. The average price that RPRX shares were previous bought at was USD 36.5322. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 2,894 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 89.52 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 89.52. The average price that RVTY shares were previous bought at was USD 92.115. The current market price is -2.8% lower than average price they were purchased at. The value of the holding in RVTY has fallen by USD 9,525 compared to the previous valuation of Revvity Inc. |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 98.7897 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 98.7897. The average price that SAN.PA shares were previous bought at was EUR 98.8748. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in SAN.PA has increased by EUR 21,661 compared to the previous valuation of Sanofi SA however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| SDZ.SW - | HOLD | 0 @ CHF 67.2036 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 67.2036. The average price that SDZ.SW shares were previous bought at was CHF 57.1581. The current market price is 17.6% higher than average price they were purchased at. The value of the holding in SDZ.SW has increased by CHF 2,194 compared to the previous valuation of however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| SHL.AX - | HOLD | 0 @ AUD 13.394 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 13.394. The average price that SHL.AX shares were previous bought at was AUD 14.8355. The current market price is -9.7% lower than average price they were purchased at. The value of the holding in SHL.AX has fallen by AUD 666 compared to the previous valuation of |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 51.1085 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 51.1085. The average price that SHL.DE shares were previous bought at was EUR 53.8357. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in SHL.DE has fallen by EUR 3,761 compared to the previous valuation of Siemens Healthineers AG |
| SIG.AX - | HOLD | 0 @ AUD 2.0188 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 2.0188. The average price that SIG.AX shares were previous bought at was AUD 1.9959. The current market price is 1.1% higher than average price they were purchased at. The value of the holding in SIG.AX has fallen by AUD 1,276 compared to the previous valuation of |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 16.2733 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 16.2733. The average price that SN.L shares were previous bought at was GBP 17.6091. The current market price is -7.6% lower than average price they were purchased at. The value of the holding in SN.L has fallen by GBP 31,844 compared to the previous valuation of Smith & Nephew PLC |
| SOBI.ST - | HOLD | 0 @ SEK 34.341 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 34.341. The average price that SOBI.ST shares were previous bought at was SEK 31.2771. The current market price is 9.8% higher than average price they were purchased at. The value of the holding in SOBI.ST has increased by SEK 1,940 compared to the previous valuation of however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 66.28 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 66.28. The average price that SOLV shares were previous bought at was USD 70.6839. The current market price is -6.2% lower than average price they were purchased at. The value of the holding in SOLV has fallen by USD 5,283 compared to the previous valuation of Solventum Corp. |
| SOON.SW - | HOLD | 0 @ CHF 267.005 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 267.005. The average price that SOON.SW shares were previous bought at was CHF 278.783. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in SOON.SW has fallen by CHF 58,683 compared to the previous valuation of |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 257.792 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 257.792. The average price that SRT3.DE shares were previous bought at was EUR 255.58. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in SRT3.DE has fallen by EUR 15,483 compared to the previous valuation of Sartorius AG |
| STE - STERIS plc | HOLD | 0 @ USD 260.06 | USD 0 | The current share valuation price of STE based on adjusted close was USD 260.06. The average price that STE shares were previous bought at was USD 226.428. The current market price is 14.9% higher than average price they were purchased at. The value of the holding in STE has increased by USD 652,648 compared to the previous valuation of STERIS plc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| STMN.SW - | HOLD | 0 @ CHF 119.886 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 119.886. The average price that STMN.SW shares were previous bought at was CHF 115.787. The current market price is 3.5% higher than average price they were purchased at. The value of the holding in STMN.SW has fallen by CHF 385 compared to the previous valuation of |
| SYK - Stryker Corporation | HOLD | 0 @ USD 353.81 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 353.81. The average price that SYK shares were previous bought at was USD 370.433. The current market price is -4.5% lower than average price they were purchased at. The value of the holding in SYK has fallen by USD 27,043 compared to the previous valuation of Stryker Corporation |
| TMO - Time Out Group plc | HOLD | 0 @ USD 565.98 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 565.98. The average price that TMO shares were previous bought at was USD 475.692. The current market price is 19.0% higher than average price they were purchased at. The value of the holding in TMO has fallen by USD 34,935 compared to the previous valuation of Time Out Group plc |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 255.254 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 255.254. The average price that UCB.BR shares were previous bought at was EUR 207.476. The current market price is 23.0% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 157,873 compared to the previous valuation of UCB SA however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| UNH - UnitedHealth Group Incorporated | HOLD | 0 @ USD 321.56 | USD 0 | The current share valuation price of UNH based on adjusted close was USD 321.56. The average price that UNH shares were previous bought at was USD 437.234. The current market price is -26.5% lower than average price they were purchased at. The value of the holding in UNH has fallen by USD 377,635 compared to the previous valuation of UnitedHealth Group Incorporated |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 454 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 454. The average price that UTHR shares were previous bought at was USD 420.31. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in UTHR has increased by USD 5,803 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 291.21 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 291.21. The average price that VEEV shares were previous bought at was USD 285.857. The current market price is 1.9% higher than average price they were purchased at. The value of the holding in VEEV has fallen by USD 111,334 compared to the previous valuation of Veeva Systems Inc Class A |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 416.25 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 416.25. The average price that VRTX shares were previous bought at was USD 422.051. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in VRTX has fallen by USD 27,219 compared to the previous valuation of Vertex Pharmaceuticals Inc |
| WAT - Waters Corporation | HOLD | 0 @ USD 371.16 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 371.16. The average price that WAT shares were previous bought at was USD 338.317. The current market price is 9.7% higher than average price they were purchased at. The value of the holding in WAT has fallen by USD 16,466 compared to the previous valuation of Waters Corporation |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 371.16 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 371.16. The average price that WAT shares were previous bought at was USD 338.317. The current market price is 9.7% higher than average price they were purchased at. The value of the holding in WAT has fallen by USD 16,466 compared to the previous valuation of MULETFWATIMETFP |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 275.34 | USD 0 | The current share valuation price of WST based on adjusted close was USD 275.34. The average price that WST shares were previous bought at was USD 267.944. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in WST has fallen by USD 12,119 compared to the previous valuation of West Pharmaceutical Services Inc |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 88.5099 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 88.5099. The average price that ZBH shares were previous bought at was USD 98.4616. The current market price is -10.1% lower than average price they were purchased at. The value of the holding in ZBH has increased by USD 3,970 compared to the previous valuation of Zimmer Biomet Holdings Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| ZTS - Zoetis Inc | HOLD | 0 @ USD 119.56 | USD 0 | The current share valuation price of ZTS based on adjusted close was USD 119.56. The average price that ZTS shares were previous bought at was USD 141.646. The current market price is -15.6% lower than average price they were purchased at. The value of the holding in ZTS has fallen by USD 78,621 compared to the previous valuation of Zoetis Inc |